Semaglutide Trial on GI Side Effect Nutrition Therapy Completed

A clinical trial involving semaglutide has reached completed status as of October 29, 2026. The study, registered as NCT06431308, is titled "Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events." The trial phase is listed as not applicable. Semaglutide remains an approved compound, and this trial focused on incretin-based anti-obesity medications more broadly. The study's stated purpose was to examine nutritional therapy approaches in relation to gastrointestinal adverse events associated with this medication class. No results have been reported as part of this update, only the change in status to completed. The trial record does not include outcome data, efficacy findings, or safety conclusions at this time. Readers should note that completion of a trial reflects the end of the study's active phase and does not by itself indicate what, if any, findings resulted from the research. Further details, when and if made available, would typically appear in subsequent updates to the trial registry or in a related publication. For additional background on this compound, readers can consult the semaglutide overview.